The Key to           Drug Discovery Success                                                The best means of reducing over...
About the Discovery Summit 2012  The    Phar ma       Network         -  marcus evans Summits group                     Of...
Upcoming SlideShare
Loading in …5
×

The Key to Drug Discovery Success by Riccardo Isola, Chief Executive Officer, Accelera: a sponsor company attending the marcus evans Discovery Summit 2012

567 views

Published on

The Key to Drug Discovery Success by Riccardo Isola, Chief Executive Officer, Accelera: a sponsor company attending the marcus evans Discovery Summit 2012, on adding value in drug discovery programmes.

Published in: Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
567
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

The Key to Drug Discovery Success by Riccardo Isola, Chief Executive Officer, Accelera: a sponsor company attending the marcus evans Discovery Summit 2012

  1. 1. The Key to Drug Discovery Success The best means of reducing overall drug different cancer indications. Interestingly, development costs is to start off with this approach is also beginning to be targets that are as fully validated as explored in other therapeutic areas, possible from a preclinical point of view, including inflammation/arthritis. and to envisage development in selected patient subpopulations, if appropriate and Another therapeutic approach, feasible. This subsequently facilitates the monoclonal antibody therapy, is still design of early clinical trials that are able holding up to its promise, and in particular to accurately predict drug activity, antibody-drug conjugates are currently of minimising the possibility of failure due to much interest, with tens of molecules in inadequate activity at later development clinical development. stages. This is a major problem today, especially in the cancer field. However, Relatively new areas that have yet to beInterview with: Riccardo Isola, this requires a willingness to kill fully exploited include gene silencingChief Executive Officer, Accelera programmes that do not live up to technologies (e.g. siRNA, miRNA), which expectations as early as possible. currently need to be optimised asThe combination of a highly innovative Therefore, intensive implementation of therapeutic agents but that could benefitand well-validated target is the key to patient selection, pharmacodynamic and enormously from recent advances in drugproject success, says Riccardo Isola, Chief pharmacological biomarkers, and stringent delivery technologies.Executive Officer, Accelera. From a clinical activity criteria are all importantsponsor company at the upcoming factors. What is your outlook for the future?marcus evans Discovery Summit 2011,Isola offers his insight into drug discovery, How could potential failures be identified Pharmacological therapy, especially for butand how pharmaceutical and biotech sooner? not limited to the field of cancer, iscompanies can add value, reduce costs increasingly likely to be based on Patient-and innovate. The combination of a highly innovative Tailored Therapy approaches, i.e. choosing and well-validated target is the key to or adjusting the most suitable course ofHow can pharmaceutical companies add project success. Beyond this, the ability to therapy based on the molecularvalue to their R&D programmes? select active compounds at early characteristics of the individual patient development stages that are optimal in and of his or her disease. Therefore,The key to value in a pipeline is that it be terms of potential ADMET liabilities is increasingly sophisticated yet generallyrich in high-quality, highly innovative what Accelera specialises in. available diagnostic approaches (such asprogrammes. Unfortunately, in an ever high-coverage DNA sequencing, analysismore competitive environment, this is no The best advice I can give is to be of circulating tumour cells, and so on) willeasy matter, especially for companies that stringent and not yield to the temptation continue to be developed anddo not have the resources to execute to carry forward sub-optimal compounds. implemented at an ever greater pace.powerful in-licensing campaigns. For small Going back to the chemistry bench is-medium companies that rely on in-house almost always the best, if not the easiest, Drug discovery scientists and organisationsproducts, it is of utmost importance to choice! need to keep fully abreast of technologicalmake firm and well-informed strategic advances in these fields, judiciouslydecisions regarding innovative areas of What are some of the scientific areas or choosing the right implementationresearch on which to focus, then to technologies worth following? policies, working closely with academiadevelop highly competitive programmes in and regulatory authorities, to ensure thatthose specific fields. In the drug discovery field, kinase the development of new therapies and the inhibitors will remain an important avenue implementation of appropriate andHow can the overall cost of drug to further exploit in the next few years. effective diagnostic approaches can resultdevelopment be reduced? Four anticancer therapies that are kinase in maximum patient benefit, as well as inhibitors were approved in 2011, for optimise development costs.
  2. 2. About the Discovery Summit 2012 The Phar ma Network - marcus evans Summits group Offering much more than any conference, exhibition or trade show, this exclusive meeting will bring together esteemed industry thought leaders and solution providers to delivers peer-to-peer information on a highly focused and interactive networking event. The Summit includes presentations strategic matters, professional trends on ensuring successful drug discovery, stimulating innovation and creating partnerships. and breakthrough innovations. www.discovery-summit.com Contact Sarin Kouyoumdjian-Gurunlian, Press Manager, marcus evans, Summits Division Please note that the Summit is a closed business event and the Tel: + 357 22 849 313 number of participants strictly Email: press@marcusevanscy.com limited. For more information please send an email to info@marcusevanscy.com All rights reserved. The above content may be republished or reproduced – kindly inform us by sending an email to press@marcusevanscy.comAbout AcceleraAccelera is a non-clinical CRO that operates as a drug development partner with biotech and pharmaceutical companies worldwide. Weknow by experience that the success of drug discovery is measured by the quality of the product candidates that are generated. Accelera’sintegrated services include Attrition Reducing Technologies (ART) and Toxicology Screening for the selection of high-quality drugcandidates.For more information, please visit: www.accelera.infoAbout marcus evans Summitsmarcus evans Summits are high level business forums for the world’s leading decision-makers to meet, learn and discuss strategies andsolutions. Held at exclusive locations around the world, these events provide attendees with a unique opportunity to individually tailor theirschedules of keynote presentations, think tanks, seminars and one-to-one business meetings.For more information, please visit: www.marcusevans.comUpcoming EventsDiscovery Summit 2012 (North America) - www.thediscoverysummit.comEvolution Asia Summit 2012 (Asia Pacific) - www.evolutionasia-summit.comEvolution Summit 2012 (Europe) - www.evolution-summit.comEvolution Summit 2012 (North America) - www.evolutionsummit.comTo view the web version of this interview please click here: www.discovery-summit.com/RiccardoIsola

×